Of the 22 ondansetron regimens, 17 were dominated. Of the remaining 5 regimens, two were dominated by extended dominance. Thus, only 3 regimens were dominant, the results for which will be reported here. The 3 regimens were:
ondansetron 1 mg orally (p.o.), three times daily for 3 days (regimen 1);
ondansetron 8 mg intravenously (i.v.) plus dexamethasone 20 mg i.v. and ondansetron 8 mg p.o. twice daily for 2 days (regimen 2); and
ondansetron 8 mg i.v. plus metoclopramide 80 mg i.v. and ondansetron 8 mg p.o. three times daily for 3 to 5 days, and prednisole 100 mg p.o. for 4 days (regimen 3).
The efficacy rates for the complete control of acute and delayed emesis with the three dominant strategies were 43.8% for regimen 1, 78.4% for regimen 2 and 90.4% for regimen 3.
The incremental effectiveness was 34.6% for regimen 2 compared with regimen 1, and 12.0% for regimen 3 compared with regimen 2.
The average cost per patient was Can$20.11 with regimen 1, Can$113.07 with regimen 2 and Can$260.49 with regimen 3.
The incremental cost per patient was Can$92.96 for regimen 2 compared with regimen 1, and Can$147.42 for regimen 3 compared with regimen 2.
The incremental cost per each additional treatment success obtained with regimen 2 compared with regimen 1 was Can$268.67.
The incremental cost per each additional treatment success obtained with regimen 3 compared with regimen 2 was Can$1,228.50.